Skip to main content
. Author manuscript; available in PMC: 2014 May 28.
Published in final edited form as: PM R. 2013 Dec 22;6(5):427–436. doi: 10.1016/j.pmrj.2013.10.009

Figure 2.

Figure 2

Images depicting sclerotic bands associated with bisphosphonate treatment. (A) A 10-year-old girl with fibrous dysplasia who was treated with a 3-year course of pamidronate was found to have transverse sclerotic bands at the radial epiphysis and metaphysis (arrow). Note the expansile, ground glass appearance of the fibrous dysplasia in her metacarpals and phalanges (arrowheads). (B) Radiographs from a 13-year-old boy with osteogenesis imperfecta who was treated with pamidronate for 2 years demonstrate metaphyseal bands in the distal femur and proximal tibia (arrows). An intramedullary rod has been placed for fixation of a femoral fracture (arrowhead). (C) A 13-year-old girl with fibrous dysplasia underwent a 1-year course of pamidronate at age 7 years, which caused residual sclerotic bands that appear to have migrated toward the tibial diaphysis with continued skeletal growth (arrow). (D) Spine films from the patient in (C) demonstrate sclerosis at the superior and inferior end plates of the vertebral bodies (arrows).